Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 40Observational 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Carcinoma, Hepatocellular 9Small Cell Lung Carcinoma 5Carcinoma, Transitional Cell 5Neoplasms 4Melanoma 3Lung Neoplasms 3Breast Neoplasms 2Unresectable Hepatocellular Carcinoma 1Triple Negative Breast Neoplasms 1Sarcopenia 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasm Metastasis 1Liver Neoplasms 1Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Blood Specimen Collection 5Drug Therapy 3Specimen Handling 2Immune Checkpoint Inhibitors 2Carboplatin 2Biopsy, Large-Core Needle 2Biopsy 2toripalimab 1tislelizumab 1taxane 1sacituzumab govitecan 1pembrolizumab 1atezolizumab 1Zoledronic Acid 1Urine Specimen Collection 1Prophylactic Mastectomy 1Paracentesis 1Neuropsychological Tests 1Mifepristone 1Medicine, Chinese Traditional 1Mastectomy, Segmental 1Magnetic Resonance Spectroscopy 1Interviews as Topic 1Immunotherapy 1Immunohistochemistry 1Gene Expression Profiling 1Doxorubicin 1DNA 1Cyclophosphamide 1Combined Modality Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Triple Negative Breast Neoplasms × atezolizumab × Clear all
NCT03232593 2022-08-24

A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)

Hoffmann-La Roche

Completed
1,758 enrolled
BreastGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡